Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C66250
http://purl.obolibrary.org/obo/NCIT_C66250
Preferred Name

Ocrelizumab
Definitions
A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning.
prefLabel
Ocrelizumab
label
Ocrelizumab
PDQ_Closed_Trial_Search_ID
780147
code
C66250
prefixIRI
NCIT:C66250
in_subset
Preferred_Name
Ocrelizumab
FDA_UNII_Code
A10SJL62JY
Contributing_Source
FDA
Maps_To
Ocrelizumab
CAS_Registry
637334-45-3
NCI_Drug_Dictionary_ID
780147
Legacy Concept Name
Ocrelizumab
type
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
780147
Semantic_Type
Pharmacologic Substance
UMLS_CUI
C1882138
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display